Clinical trial
Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma
NCT06861894 is registered in ClinicalTrials.gov with Zhigang Li as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma
- Lead sponsor
- Zhigang Li
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- July 31, 2025
- Completion date
- March 31, 2029
- Enrollment
- 164 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.